Targeting CXCR1/2 in autologous islet transplant recipients
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Several cytokines and chemokines are elevated after islet infusion in patients undergoing total pancreatectomy with islet autotransplantation (TPIAT), including CXCL8 (also known as interleukin-8), leading to islet loss.

Researchers investigated whether the use of reparixin for blockade of the CXCL8 pathway would improve islet engraftment and insulin independence after TPIAT.

Adults without diabetes scheduled for TPIAT at 9 academic centers were randomized to a continuous infusion of reparixin or placebo for 7 days in the peri-transplant period. Efficacy measures included insulin independence, insulin dose, hemoglobin A1c (HbA1c), and mixed meal tolerance testing. The intent-to-treat population included 102 participants, n=50 reparixin-treated, n=52 placebo-treated.

--The proportion insulin-independent at day 365 was similar in reparixin and placebo: 20% vs 21%.

--27/42 in the reparixin group and 28/45 in the placebo group maintained HbA1c ≤6.5%.

--Area under the curve C-peptide from mixed meal testing was similar between groups, as were adverse events.

In conclusion, reparixin infusion did not improve diabetes outcomes. CXCL8 inhibition alone may be insufficient to prevent islet damage from innate inflammation in islet autotransplantation.

American Journal of Transplantation
Source: https://doi.org/10.1111/ajt.16695
Like
Comment
Share